EP1565200A4 - NUCLEINE SUSSE CORRESPONDING PROTEIN 24P4C12 FOR THE TREATMENT AND DETECTION OF CANCER - Google Patents

NUCLEINE SUSSE CORRESPONDING PROTEIN 24P4C12 FOR THE TREATMENT AND DETECTION OF CANCER

Info

Publication number
EP1565200A4
EP1565200A4 EP02789937A EP02789937A EP1565200A4 EP 1565200 A4 EP1565200 A4 EP 1565200A4 EP 02789937 A EP02789937 A EP 02789937A EP 02789937 A EP02789937 A EP 02789937A EP 1565200 A4 EP1565200 A4 EP 1565200A4
Authority
EP
European Patent Office
Prior art keywords
susse
nucleine
cancer
detection
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02789937A
Other languages
German (de)
French (fr)
Other versions
EP1565200A2 (en
Inventor
Arthur B Raitano
Karen Jane Meyrick Morrison
Wangmao Ge
Pia M Challita-Eid
Aya Jakobovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of EP1565200A2 publication Critical patent/EP1565200A2/en
Publication of EP1565200A4 publication Critical patent/EP1565200A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP02789937A 2002-11-27 2002-11-27 NUCLEINE SUSSE CORRESPONDING PROTEIN 24P4C12 FOR THE TREATMENT AND DETECTION OF CANCER Withdrawn EP1565200A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/038264 WO2004050828A2 (en) 2002-11-27 2002-11-27 Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer

Publications (2)

Publication Number Publication Date
EP1565200A2 EP1565200A2 (en) 2005-08-24
EP1565200A4 true EP1565200A4 (en) 2009-06-24

Family

ID=32467113

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02789937A Withdrawn EP1565200A4 (en) 2002-11-27 2002-11-27 NUCLEINE SUSSE CORRESPONDING PROTEIN 24P4C12 FOR THE TREATMENT AND DETECTION OF CANCER

Country Status (6)

Country Link
EP (1) EP1565200A4 (en)
JP (1) JP2006508163A (en)
AU (3) AU2002352976B2 (en)
CA (1) CA2503346C (en)
IL (1) IL167892A (en)
WO (1) WO2004050828A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2185574T3 (en) * 2007-09-07 2013-08-05 Agensys Inc Antibodies and related molecules that bind to 24P4C12 proteins
WO2010111018A1 (en) * 2009-03-06 2010-09-30 Agensys, Inc. Antibody drug conjugates (adc) that bind to 24p4c12 proteins
JP2013049646A (en) * 2011-08-30 2013-03-14 Tokyo Medical Univ Cancer therapeutic agent
AU2016332352A1 (en) * 2015-10-02 2018-04-12 Memorial Sloan-Kettering Cancer Center Small molecules blocking histone reader domains
CN109073635A (en) 2016-01-25 2018-12-21 豪夫迈·罗氏有限公司 Method for Assaying T Cell Dependent Bispecific Antibodies
JP7184259B2 (en) * 2017-04-28 2022-12-06 学校法人藤田学園 Allergic antigens and their epitopes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061746A1 (en) * 1999-04-12 2000-10-19 Agensys, Inc. 13 transmembrane protein expressed in prostate cancer
WO2001046258A2 (en) * 1999-12-23 2001-06-28 Incyte Genomics, Inc. Transporters and ion channels

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE157012T1 (en) 1989-11-03 1997-09-15 Univ Vanderbilt METHOD FOR THE IN VIVO ADMINISTRATION OF FUNCTIONAL FOREIGN GENES
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
SE9002480D0 (en) 1990-07-23 1990-07-23 Hans Lilja ASSAY OF FREE AND COMPLEXED PROSTATE-SPECIFIC ANTIGEN
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CU22559A1 (en) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech EXPRESSION SYSTEM OF HETEROLOGICAL ANTIGENS IN E. COLI AS FUSION PROTEINS
JP2001504799A (en) 1996-03-11 2001-04-10 エピミューン インコーポレイテッド Peptides with increased binding affinity to HLA molecules
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
EP1000148A2 (en) * 1997-08-01 2000-05-17 Genset 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061746A1 (en) * 1999-04-12 2000-10-19 Agensys, Inc. 13 transmembrane protein expressed in prostate cancer
WO2001046258A2 (en) * 1999-12-23 2001-06-28 Incyte Genomics, Inc. Transporters and ion channels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004050828A2 *

Also Published As

Publication number Publication date
AU2002352976B2 (en) 2007-11-08
AU2008200628A1 (en) 2008-03-06
CA2503346C (en) 2014-03-18
AU2002352976A1 (en) 2004-06-23
AU2008200628B2 (en) 2009-05-07
JP2006508163A (en) 2006-03-09
WO2004050828A3 (en) 2004-12-09
AU2009208065A1 (en) 2009-08-27
EP1565200A2 (en) 2005-08-24
AU2009208065B2 (en) 2012-05-24
CA2503346A1 (en) 2004-06-17
WO2004050828A2 (en) 2004-06-17
IL167892A (en) 2012-06-28

Similar Documents

Publication Publication Date Title
ATE468331T1 (en) NEW CYANOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER DISEASES
DE602004010407D1 (en) FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYL-UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND SUFFERING
DE60335293D1 (en) PYRROLOPYRIDAZINE COMPOUNDS AND USE METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES
ATE551100T1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CARDIOVASCULAR AND CEREBROVASCULAR DISEASES
ATE542801T1 (en) 2,4-PYRIMIDIINDIAMINES SUITABLE FOR THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISEASES AND DISEASES OF THE IMMUNE SYSTEM
ATE381347T1 (en) COMBINATIONS OF EZETIMIBE AND ASPIRIN FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
DE602004028763D1 (en) TE FOR THE TREATMENT OF VIRUS DISEASES
DE60313297D1 (en) DEVICE FOR IDENTIFICATION AND TREATMENT OF SYNKOPE
EP1701664A4 (en) SYSTEM AND METHOD FOR THE TREATMENT OF TISSUE
DE50212701D1 (en) IRRADATION ARRANGEMENT FOR THE TREATMENT OF ACNE AND AKNENARBEN
ATE494279T1 (en) PYRIMIDE DERIVATIVES SUITABLE FOR THE TREATMENT OF CRTH2-MEDIATED DISEASES
ATE389649T1 (en) SUBSTITUTED AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ANGIONESIS-RELATED DISEASES
DE602004022061D1 (en) USE OF MODIFIED CYCLOSPORINES FOR THE TREATMENT OF HCV DISEASES
DE60124302D1 (en) THIAZONE DERIVATIVES FOR THE TREATMENT OF PPAR-LIFE DISEASES
EP1626730A4 (en) METHOD, DEVICE AND COMPOSITION FOR THE TREATMENT OF ACNE
EA200500098A1 (en) MEDICINE AND METHOD FOR THE TREATMENT OF THE PATHOLOGICAL SYNDROME
DE60030554T8 (en) USES OF ET743 FOR THE TREATMENT OF CANCER
DE60229959D1 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
ATE443704T1 (en) PYRIDOPYRIMIDINONE FOR THE TREATMENT OF CANCER DISEASES
DE60136477D1 (en) RETINOIDES FOR THE TREATMENT OF EMPHYSEM
EP1487480A4 (en) FUSION MOLECULES AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
EP1694364A4 (en) SYSTEM FOR THE TREATMENT AND PREVENTION OF BREAST CANCER
DE602004001134D1 (en) TETRAZOL DERIVATIVES AND METHOD FOR THE TREATMENT OF METABOLISM-RELATED DISEASES THEREWITH
DE60027429D1 (en) DIHYDROBENZODIAZEPINES AND THEIR USE FOR THE TREATMENT OF DYSLIPIDIA
DE60016047D1 (en) DIHYDROBENZOPYRANE, DIHYDROBENZOTHIOPYRANE AND TETRAHYDROCHINOLINE FOR THE TREATMENT OF COX-2-DEPENDENT DISEASES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050421

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090525

17Q First examination report despatched

Effective date: 20090923

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AGENSYS, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150304

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150715